Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Year: 2022
Type: conference-abstract
Source: Cancer Research
Authors: Javier Cortés, Aditya Bardia, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Sara A. Hurvitz, Adam Brufsky, Sagar Sardesai, Kevin M Kalinsky, Tiffany Traina, Erika Hamilton, Joyce O’Shaughnessy, Véronique Diéras, Lisa A. Carey, Martine Piccart, Sibylle Loibl, Hope S. Rugo, Yanni Zhu, See Phan, Luca Gianni
Institutions: Harvard University, Massachusetts General Hospital, Institut Curie, Dana-Farber Cancer Institute, Universitair Ziekenhuis Leuven, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Magee-Womens Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, The Ohio State University Wexner Medical Center, Emory University, Winship Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon, Tennessee Oncology, Baylor University Medical Center, Centre Eugène Marquis, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Université Libre de Bruxelles, Institut Jules Bordet, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Gilead Sciences (United States)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4220964307